MGNX vs. XERS, ENTA, CTNM, INZY, NLTX, XBIT, EBS, AQST, RANI, and EPIX
Should you be buying MacroGenics stock or one of its competitors? The main competitors of MacroGenics include Xeris Biopharma (XERS), Enanta Pharmaceuticals (ENTA), Contineum Therapeutics (CTNM), Inozyme Pharma (INZY), Neoleukin Therapeutics (NLTX), XBiotech (XBIT), Emergent BioSolutions (EBS), Aquestive Therapeutics (AQST), Rani Therapeutics (RANI), and ESSA Pharma (EPIX). These companies are all part of the "pharmaceutical preparations" industry.
Xeris Biopharma (NASDAQ:XERS) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, community ranking, risk, valuation, analyst recommendations, media sentiment and institutional ownership.
In the previous week, MacroGenics had 25 more articles in the media than Xeris Biopharma. MarketBeat recorded 25 mentions for MacroGenics and 0 mentions for Xeris Biopharma. MacroGenics' average media sentiment score of 0.00 beat Xeris Biopharma's score of -0.03 indicating that Xeris Biopharma is being referred to more favorably in the media.
42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 96.9% of MacroGenics shares are held by institutional investors. 4.6% of Xeris Biopharma shares are held by insiders. Comparatively, 11.3% of MacroGenics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Xeris Biopharma has a net margin of -37.58% compared to Xeris Biopharma's net margin of -53.60%. Xeris Biopharma's return on equity of -98.01% beat MacroGenics' return on equity.
Xeris Biopharma presently has a consensus price target of $4.63, indicating a potential upside of 133.59%. MacroGenics has a consensus price target of $13.67, indicating a potential upside of 213.10%. Given Xeris Biopharma's higher possible upside, analysts clearly believe MacroGenics is more favorable than Xeris Biopharma.
MacroGenics has lower revenue, but higher earnings than Xeris Biopharma. MacroGenics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.
Xeris Biopharma has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500. Comparatively, MacroGenics has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500.
MacroGenics received 280 more outperform votes than Xeris Biopharma when rated by MarketBeat users. However, 69.65% of users gave Xeris Biopharma an outperform vote while only 63.06% of users gave MacroGenics an outperform vote.
Summary
MacroGenics beats Xeris Biopharma on 10 of the 18 factors compared between the two stocks.
Get MacroGenics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MacroGenics Competitors List
Related Companies and Tools
